J&J Natrecor "Dear Doctor" Letter Discusses Appropriate Use In Heart Failure
This article was originally published in The Pink Sheet Daily
Executive Summary
Scios uses "Dear Doctor" letter to alert physicians to independent panel's recommendations for appropriate and inappropriate uses of nesiritide. The letter recommends use of Natrecor only in a clinical setting where blood pressure can be closely monitored.
You may also be interested in...
Scios Overhauls Natrecor Physician Promotion
The Johnson & Johnson subsidiary's program for its congestive heart failure agent includes sales force training and new promotional materials that reflect expert panel recommendations on nesiritide use.
Scios Overhauls Natrecor Physician Promotion
The Johnson & Johnson subsidiary's program for its congestive heart failure agent includes sales force training and new promotional materials that reflect expert panel recommendations on nesiritide use.
Natrecor Sales & Marketing Subject Of Federal Prosecutor's Subpoena
U.S. Attorney's Office in Boston is seeking "documents related to the sales and marketing" of the congestive heart failure therapy, J&J division Scios says. Subpoena announcement comes on the heels of a journal article asserting that Scios engaged in a marketing campaign for outpatient use of the drug, which the company denies.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: